BTIG analyst Mark Massaro has reiterated their neutral stance on CERS stock, giving a Hold rating on November 8.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mark Massaro has given his Hold rating due to a combination of factors affecting Cerus’s stock. The company reported strong growth in its Q3 earnings, with significant revenue increases driven by its INTERCEPT platelets and IFC products. However, despite these positive results, the anticipated timelines for the CE marking of INTERCEPT Red Blood Cells in Europe have been delayed by at least six months, which is seen as a critical catalyst for the stock’s future performance.
Additionally, while Cerus’s shares are trading below the average of its small-cap peers, suggesting a fair valuation, the uncertainty surrounding the regulatory approval process in Europe and the U.S. contributes to the Hold rating. The transition of the competent authority review from the Czech Republic to France is expected to further delay the process, potentially pushing the CE marking to 2027 and U.S. FDA approval to 2028. Given these mixed signals, Massaro maintains a Neutral stance, recognizing both the company’s growth potential and the challenges it faces.
According to TipRanks, Massaro is an analyst with an average return of -4.7% and a 34.43% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Lucid Diagnostics, Guardant Health, and Cerus.
In another report released on November 8, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.50 price target.